ConductScience.org, home

Comparison · NCT00878995-dc32137f

Arm I: Standard of Care Therapy + Placebo Testosterone vs Arm II: Standard of Care Therapy + Testosterone: 1-year Survival

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm I: Standard of Care Therapy + Placebo Testosterone vs Arm II: Standard of Care Therapy + Testosterone: 1-year Survival. Trial comparisons, record NCT00878995-dc32137f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00878995-dc32137f

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5830.320.807wilson
Risk in group 20.60.3130.832wilson
Risk difference, group 1 minus group 2-0.0167-0.3680.347newcombe hybrid score
Risk ratio, group 1 over group 20.9720.4851.95log
Odds ratio, group 1 over group 20.9330.1695.15log
Number needed to treat, for one fewer participant with the outcome on Arm I: Standard of Care Therapy + Placebo Testosterone than on Arm II: Standard of Care Therapy + Testosterone60from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm I: Standard of Care Therapy + Placebo Testosterone
Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.~Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone: Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone
712OG000
Group 2Arm II: Standard of Care Therapy + Testosterone
Patients receive standard of care chemotherapy and/or radiation plus testosterone intramuscularly (IM) weekly for 7 weeks.~Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate: Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate
610OG001

Outcome

Type
SECONDARY
Title
1-year Survival
Description
Number of participants who survived one year post study.
Time frame
1 year post study
Population
12 subjects started each group. 2 subjects withdrew after baseline from the testosterone group.

Source ClinicalTrials.gov

Trial

Title
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
NCT number
NCT00878995
Phases
PHASE1
Conditions
Cachexia, Squamous Cell Carcinoma
Interventions
Placebo Testosterone, Testosterone Enanthate 100 MG/ML
Lead sponsor
The University of Texas Medical Branch, Galveston
Results first posted
2018-03-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00878995-dc32137f